Development

Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.”

The best strategy is to use a combination of complementary methods.

The company will be introducing its new low-substituted hydroxypropyl cellulose and its improved polyplasdone LN superdisintegrant at the October 2024 events.

Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.

This premiere episode of Sexy Science in Pharmaceuticals features Professor Jonathan Pokorski, UC San Diego Jacobs School of Engineering, and Dr. James DiNunzio, Senior Principal Scientist at Merck & Co., Inc. in Rahway, NJ, discussing the benefits of hot-melt extrusion.

Solving the challenge of better-stabilized temperature-sensitive biomolecules hinges on innovative formulation strategies.

Webinar Date/Time: Wed, Oct 16, 2024 11:00 AM EDT

Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.

New and existing technologies, as well as a patient-centric focus, are pushing drug formulation into exciting directions.

Novo Nordisk will use Korro Bio’s OPERA platform to develop RNA editing candidates for two targets to treat cardiometabolic diseases.

Webinar Date/Time: Fri, Sep 27, 2024 11:00 AM EDT

Greater collaboration and understanding are needed to ensure the correct grade of excipient is used in drug products.

In this paper, the authors introduce a method that combines ion exchange chromatography with an easier-to-perform, simpler one-step post-column derivatization that is selective to nitrite and visible spectrophotometric detection to allow high sample loading volumes without affecting resolution.

Insights into molecular behaviors and predictive capabilities are bringing numerous benefits.

Qualifying material suppliers is a crucial step in ensuring safe and effective drug products.

Webinar Date/Time: Tue, Sep 24, 2024 11:00 AM EDT

The completed acquisition of Morphic expands Lilly's immunology pipeline with Morphic's oral integrin therapies for treating inflammatory bowel disease.

Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy.

The collaboration builds on Novartis’ acquisition of Chinook Therapeutics just over a year ago.

The approvals and authorizations come amid a late summer surge in the virus that is tracking a bit earlier than the early fall wave in the US in 2023.

Merck, known as MSD outside of the United States and Canada, will gain CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical in a deal potentially worth up to $1.3 billion.

The combination of Opdivo plus Yervoy is already established as a second-line treatment for patients with advanced hepatocellular carcinoma.

For a preview of what's to come at the AAPS PharmSci 360 show in October, Pharmaceutical Technology® spoke with Vivek Gupta, PhD, associate dean for Graduate Education and Research, associate professor, Pharmaceutical Sciences, St. John’s University, Queens, New York, about the formulation of inhalation dosage forms.

Webinar Date/Time: Tue, Oct 22, 2024 11:00 AM EDT

Webinar Date/Time: Tue, Sep 24, 2024 10:00 AM EDT 7am PDT | 3pm BST | 4pm CEST

Approximately 15% of all lung cancers diagnosed in the US are of the small-cell variety, and of those, 70% are considered extensive-stage.

Genentech will have access to Sangamo’s capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines for certain neurodegenerative diseases.

Breyanzi demonstrated an overall high response rate in adults with relapsed or refractory follicular lymphoma in a Phase II study.

The agreement specifies that Nanoform will provide non-GMP nanomaterial to Takeda for in-vivo studies, the first results of which should be delivered by early 2025.

A Phase III study showed that 62% of patients given Livdelzi achieved the primary endpoint of composite biochemical response after 12 months, compared to 20% of participants taking placebo.